Advances in neurobiology of the neuromuscular junction: Implications for the anesthesiologist

Anesthesiology

Volumn 96, Issue 1, 2002, Pages 202-231

  Naguib, Mohamed ^a   Flood, Pamela ^b   McArdle, Joseph J ^c   Brenner, H R ^d  

^a UNIVERSITY OF IOWA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CALCIUM ION; CHOLINERGIC RECEPTOR; NICOTINIC RECEPTOR; POTASSIUM ION; SODIUM CHANNEL; SODIUM ION;

AGING; ANESTHESIA MECHANISM; CALCIUM SIGNALING; CRITICAL ILLNESS; ENDOCYTOSIS; GUILLAIN BARRE SYNDROME; HUMAN; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOPATHY; NERVE CELL DIFFERENTIATION; NEUROBIOLOGY; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SYNAPSE VESICLE; SYNAPTOGENESIS;

EID: 0036139685     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200201000-00035     Document Type: Review

References (380)

1. Development of the vertebrate neuromuscular junction
2. Acetylcholine receptor gene expression at the developing neuromuscular junction
3. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor
4. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor
5. Fast events in single-channel currents activated by acetylcholine and its analogues at the frog muscle end-plate
6. Embryonic acetylcholine receptors guarantee spontaneous contractions in rat developing muscle
7. Neuromuscular transmission in new-born rats
8. Nicotinic acetylcholine receptors in vertebrate muscle: Properties, distribution and neural control
9. Imprinting of acetylcholine receptor messenger RNA accumulation in mammalian neuromuscular synapses
10. Selective expression of an acetylcholine receptor-lacZ transgene in synaptic nuclei of adult muscle fibers
11. Calcium permeability increase of endplate channels in rat muscle during postnatal development
12. Neural factors regulate AChR subunit mRNAs at rat neuromuscular synapses
13. Calcium influx and protein phosphorylation mediate the metabolic stabilization of synaptic acetylcholine receptors in muscle
14. Long-term synapse loss induced by focal blockade of postsynaptic receptors
15. Gradual loss of synaptic cartels precedes axon withdrawal at developing neuromuscular junctions
16. Alterations in synaptic strength preceding axon withdrawal
17. Formation of neuromuscular junctions in adult rats: Role of postsynaptic impulse activity
18. Hebbian mechanisms revealed by electrical stimulation at developing rat neuromuscular junctions
19. Reinnervation of muscle fiber basal lamina after removal of myofibers: Differentiation of regenerating axons at original synaptic sites
20. Acetylcholine receptors in regenerating muscle accumulate at original synaptic sites in the absence of the nerve
21. Identification of agrin, a synaptic organizing protein from Torpedo electric organ
22. The agrin hypothesis
23. Structure and expression of a rat agrin
24. cDNA that encodes active agrin
25. An amino-terminal extension is required for the secretion of chick agrin and its binding to extracellular matrix
26. The agrin gene codes for a family of basal lamina proteins that differ in function and distribution
27. RNA splicing regulates agrin-mediated acetylcholine receptor clustering activity on cultured myotubes
28. Acetylcholine receptor-aggregating activity of agrin isoforms and mapping of the active site
29. Agrin binds to the nerve-muscle basal lamina via laminin
30. Agrin isoforms with distinct amino termini: Differential expression, localization, and function
31. Agrin acts via a MuSK receptor complex
32. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice
33. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo
34. Kinase domain of the muscle-specific receptor tyrosine kinase (MuSK) is sufficient for phosphorylation but not clustering of acetylcholine receptors: Required role for the MuSK ectodomain?
35. The submembrane machinery for nicotinic acetylcholine receptor clustering
36. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice
37. Rapsyn is required for MuSK signaling and recruits synaptic components to a MuSK-containing scaffold
38. Muscular dystrophies and the dystrophin-glycoprotein complex
39. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice
40. Maturation and maintenance of the neuromuscular synapse: Genetic evidence for roles of the dystrophin-glycoprotein complex
41. Transcriptional regulation of the prothrombin gene in muscle
42. The thrombin receptor mediates functional activity-dependent neuromuscular synapse reduction via protein kinase C activation in vitro
43. A molecular mechanism for synapse elimination: Novel inhibition of locally generated thrombin delays synapse loss in neonatal mouse muscle
44. Proteolytic action of thrombin is required for electrical activity-dependent synapse reduction
45. Thrombin receptor induction by injury-related factors in human skeletal muscle cells
46. Protein kinase C-mediated changes in synaptic efficacy at the neuromuscular junction in vitro: The role of postsynaptic acetylcholine receptors
47. Involvement of calpains in the destabilization of the acetylcholine receptor clusters in rat myotubes
48. Synapse-specific expression of acetylcholine receptor genes and their products at original synaptic sites in rat soleus muscle fibres regenerating in the absence of innervation
49. Synaptic basal lamina contains a signal for synapse-specific transcription
50. ARIA: A neuromuscular junction neuregulin
51. Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses
52. Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development
53. Agrin can mediate acetylcholine receptor gene expression in muscle by aggregation of muscle-derived neuregulins
54. ARIA can be released from extracellular matrix through cleavage of a heparin-binding domain
55. ARIA/HRG regulates AChR epsilon subunit gene expression at the neuromuscular synapse via activation of phosphatidylinositol 3-kinase and Ras/MAPK pathway
56. Heregulin-stimulated acetylcholine receptor gene expression in muscle: Requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity
57. Identification of a DNA element determining synaptic expression of the mouse acetylcholine receptor delta-subunit gene
58. Identification of an element crucial for the sub-synaptic expression of the acetylcholine receptor epsilon-subunit gene
59. Identification of an element required for acetylcholine receptor-inducing activity (ARIA)-induced expression of the acetylcholine receptor epsilon subunit gene
60. Implication of a multisubunit Ets-related transcription factor in synaptic expression of the nicotinic acetylcholine receptor
61. The Ets transcription factor GABP is required for postsynaptic differentiation in vivo
62. The number of Na+ channels in cultured chick muscle is increased by ARIA, an acetylcholine receptor-inducing activity
63. Substrate-bound agrin induces expression of acetylcholine receptor epsilon-subunit gene in cultured mammalian muscle cells
64. Induction by agrin of ectopic and functional postsynaptic-like membrane in innervated muscle
65. Neural agrin induces ectopic postsynaptic specializations in innervated muscle fibers
66. Agrin-induced postsynaptic-like apparatus in skeletal muscle fibers in vivo
67. Neuregulins and erbB receptors at neuromuscular junctions and at agrin-induced postsynaptic-like apparatus in skeletal muscle
68. Constitutively active MuSK is clustered in the absence of agrin and induces ectopic postsynaptic-like membranes in skeletal muscle fibers
69. Presynaptic differentiation induced in cultured neurons by local application of basic fibroblast growth factor
70. Agrin is a differentiation-inducing "stop signal" for motoneurons in vitro
71. Evidence that agrin directly influences presynaptic differentiation at neuromuscular junctions in vitro
72. Alternatively spliced isoforms of nerve- and muscle-derived agrin: Their roles at the neuromuscular junction
73. Synaptic laminin prevents glial entry into the synaptic cleft
74. Disruption of Trkb-mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junctions
75. Nerve terminal withdrawal from rat neuromuscular junctions induced by neuregulin and Schwann cells
76. Regenerating muscle fibers induce directional sprouting from nearby nerve terminals: Studies in living mice
77. Nerve sprouting in muscle is induced and guided by processes extended by Schwann cells
78. Complete mRNA coding sequence of the acetylcholine binding alpha-subunit of Torpedo marmorata acetylcholine receptor: A model for the transmembrane organization of the polypeptide chain
79. Structural homology of Torpedo californica acetylcholine receptor subunits
80. Cloning, sequencing and expression of cDNA for a novel subunit of acetylcholine receptor from calf muscle
81. The ion channel of the nicotinic acetylcholine receptor is formed by the homologous helices M II of the receptor subunits
82. d-Tubocurarine binding sites are located at alpha-gamma and alpha-delta subunit interfaces of the nicotinic acetylcholine receptor
83. Identification of equivalent residues in the gamma, delta, and epsilon subunits of the nicotinic receptor that contribute to alpha- bungarotoxin binding
84. Spontaneous and agonist-induced openings of an acetylcholine receptor channel composed of bovine muscle alpha-, beta- and delta-subunits
85. Activation of Torpedo acetylcholine receptors expressed in mouse fibroblasts: Single channel current kinetics reveal distinct agonist binding affinities
86. Mapping the conformational wave of acetylcholine receptor channel gating
87. The extracellular linker of muscle acetylcholine receptor channels is a gating control element
88. Depolarising effect of curate on embryonic rat muscles
89. Curare can open and block ionic channels associated with cholinergic receptors
90. Congenital myasthenic syndrome caused by a mutation in the Ets-binding site of the promoter region of the acetylcholine receptor epsilon subunit gene
91. Acetylcholine receptor epsilon-subunit deletion causes muscle weakness and atrophy in juvenile and adult mice
92. Deficient development and maintenance of postsynaptic specializations in mutant mice lacking an 'adult' acetylcholine receptor subunit
93. Different functions of fetal and adult AChR subtypes for the formation and maintenance of neuromuscular synapses revealed in epsilon-subunit-deficient mice
94. Nicotinic acetylcholine receptor superfamily of ligand-gated ion channels
95. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins
96. Five subunit genes of the human muscle nicotinic acetylcholine receptor are mapped to two linkage groups on chromosomes 2 and 17
97. Differential expression patterns of five acetylcholine receptor subunit genes in rat muscle during development
98. Developmental regulation of five subunit specific mRNAs encoding acetylcholine receptor subtypes in rat muscle
99. ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: Differential expression at the endplate
100. Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/heregulin, and its putative receptors. ErbB2 and ErbB3, in developing mammalian muscle
101. Gating properties of acetylcholine receptors at developing rat endplates
102. Differential regulation of muscle acetylcholine receptor gamma- and epsilon-subunit mRNAs
103. Maturation of the acetylcholine receptor in skeletal muscle: Regulation of the AChR gamma-to-epsilon switch
104. Structural basis of the different gating kinetics of fetal and adult acetylcholine receptors
105. Calcium permeability of the nicotinic acetylcholine receptor: The single-channel calcium influx is significant
106. Postsynaptic elevation of calcium induces persistent depression of developing neuromuscular synapses
107. Agonist-induced myopathy at the neuromuscular junction is mediated by calcium
108. Glutamate neurotoxicity in cortical cell culture is calcium dependent
109. Calcium-mediated myopathy at neuromuscular junctions of normal and dystrophic muscle
110. Muscarinic acetylcholine receptor-mediated induction of zif268 mRNA in PC12D cells requires protein kinase C and the influx of extracellular calcium
111. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and Na+: Implications for neurodegeneration
112. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome
113. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit
114. Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity
115. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor
116. Mode switching kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the human acetylcholine receptor epsilon subunit
117. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles: Evidences for a compensatory mechanism triggered by receptor loss
118. Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes
119. Nitric oxide is involved in acetylcholinesterase inhibitor-induced myopathy in rats
120. Reconstitution of a functional acetylcholine receptor: Conservation of the conformational and allosteric transitions and recovery of the permeability response: Role of lipids
121. Structural-functional correlates of the nicotinic acetylcholine receptor and its lipid microenvironment
122. Annular and nonannular binding sites for cholesterol associated with the nicotinic acetylcholine receptor
123. The effect of cholesterol on agonist-induced flux in reconstituted acetylcholine receptor vesicles
124. Lipid environment of acetylcholine receptor from Torpedo californica
125. The cholesterol dependence of activation and fast desensitization of the nicotinic acetylcholine receptor
126. Cells defective in sphingolipids biosynthesis express low amounts of muscle nicotinic acetylcholine receptor
127. Effects of 20,25-diazacholesterol treatment on the decay of end-plate currents
128. Overview of the physiology of the neuromuscular junction
129. Lipid modulation of nicotinic acetylcholine receptor function: The role of neutral and negatively charged lipids
130. Disclosure of discrete sites for phospholipid and sterols at the protein-lipid interface in native acetylcholine receptor-rich membrane
131. Identifying the cholesterol binding domain in the nicotinic acetylcholine receptor with [1251]azido-cholesterol
132. The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface
133. Effect of organochlorine insecticides on nicotinic acetylcholine receptor-rich membranes
134. Mutations in the M4 domain of the Torpedo californica nicotinic acetylcholine receptor alter channel opening and closing
135. Reconstitution of acetylcholine receptor from Torpedo Californica with highly purified phospholipids: Effect of alpha-tocopherol, phylloquinone, and other terpenoid quinones
136. Acetylcholine transport: Fundamental properties and effects of pharmacologic agents
137. Sources of adenosine released during neuromuscular transmission in the rat
138. Acetylcholine, ATP, and proteoglycan are common to synaptic vesicles isolated from the electric organs of electric eel and electric catfish as well as from rat diaphragm
139. Prejunctional adenosine and ATP receptors
140. The effects of adenosine triphosphate and adenosine diphosphate on transmission at the rat and frog neuromuscular junctions
141. Ion channel genes and human neurological disease: Recent progress, prospects, and challenges
142. Voltage sensor of excitation-contraction coupling in skeletal muscle
143. Ryanodine receptors of striated muscles: A complex channel capable of multiple interactions
144. Voltage-gated ion channels and hereditary disease
145. Physiology of nitric oxide in skeletal muscle
146. Voltage-gated ion channelopathies: Inherited disorders caused by abnormal sodium, chloride, and calcium regulation in skeletal muscle
147. The role of non-quantal release of acetylcholine in regulation of postsynaptic membrane electrogenesis
148. Essential functions of synapsins I and II in synaptic vesicle regulation
149. Proteins involved in synaptic vesicle trafficking
150. Short-term synaptic plasticity is altered in mice lacking synapsin I
151. The synaptic vesicle cycle: A cascade of protein-protein interactions
152. Formation of synaptic vesicles
153. Regulation by synapsin I and Ca(2+)-calmodulin-dependent protein kinase II of the transmitter release in squid giant synapse
154. Strategic location of calcium channels at transmitter release sites of frog neuromuscular synapses
155. Synaptotagmin I: A major Ca2+ sensor for transmitter release at a central synapse
156. Interactions between presynaptic calcium channels and proteins implicated in synaptic vesicle trafficking and exocytosis
157. Morphologically docked synaptic vesicles are reduced in synaptotagmin mutants of Drosophila
158. SNAP receptors implicated in vesicle targeting and fusion
159. Neurotoxins affecting neuroexocytosis
160. Syntaxin: A synaptic protein implicated in docking of synaptic vesicles at presynaptic active zones
161. Interaction of synaptotagmin with the cytoplasmic domains of neurexins
162. Clostridial toxins as therapeutic agents: Benefits of nature's most toxic proteins
163. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen
164. The role of Rab3A in neurotransmitter release
165. Calcium ions, active zones and synaptic transmitter release
166. Coupling calcium to SNARE-mediated synaptic vesicle fusion
167. Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junction
168. The structural era of endocytosis
169. Synaptic transmission: Kinetics of synaptic-vesicle recycling
170. The membrane fusion machine and neurotransmitter release
171. Synaptic vesicles: Is kissing a matter of competence?
172. Recycling and refilling of transmitter quanta at the frog neuromuscular junction
173. Optical analysis of synaptic vesicle recycling at the frog neuromuscular junction
174. Acetylcholinesterase
175. Conformation gating as a mechanism for enzyme specificity
176. Neural regulation of muscle acetylcholinesterase is exerted on the level of its mRNA
177. Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries
178. Cholinesterase is associated with the basal lamina at the neuromuscular junction
179. Synaptic structure and development: The neuromuscular junction
180. Local control of acerylcholinesterase gene expression in multinucleated skeletal muscle fibers: Individual nuclei respond to signals from the overlying plasma membrane
181. Regulation of acetylcholinesterase synthesis and assembly by muscle activity: Effects of tetrodotoxin
182. Action of veratridine on acetylcholinesterase in cultures of rat muscle cells
183. Control of junctional acetylcholinesterase by neural and muscular influences in the rat
184. Junctional form of acetylcholinesterase restored at nerve-free endplates
185. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini
186. Anticholinesterase induces nicotinic receptor modulation
187. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release
188. Analysis of the organophosphate-induced electromyographic response to repetitive nerve stimulation: Paradoxical response to edrophonium and D-tubocurarine
189. The stress of Gulf War syndrome
190. Multiple effects of 2,3-butanedione monoxime
191. Studies on cholinesterase. VII. The active surface of acetylcholine esterase derived from effects of pH on inhibitors
192. The inhibitory effect of stilbamidine, curare and related compounds and its relationship to the active groups of acetylcholine esterase
193. Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism
194. The interaction of tensilon and neostigmine with acetylcholinesterase
195. Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-induced neuromuscular blockade
196. Interactions of edrophonium, physostigmine and methanesulfonyl fluoride with the snake end-plate acetylcholine receptor-channel complex
197. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex. II. Patch clamp studies
198. Aging and muscle loss
199. Age-related sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins
200. Effects of resistance training on strength, power, and selected functional abilities of women aged 75 and older
201. Electron paramagnetic resonance reveals age-related myosin structural changes in rat skeletal muscle fibers
202. Human skeletal sarcoplasmic reticulum Ca2+ uptake and muscle function with aging and strength training
203. Ultrastructural studies of young and old mouse neuromuscular junctions
204. Compensatory plasticity of aging at the neuromuscular junction
205. Progression of age changes in synaptic transmission at mouse neuromuscular junctions
206. Sustained transmitter output by increased transmitter turnover in limb muscles of old mice
207. Excitation-calcium release uncoupling in aged single human skeletal muscle fibers
208. Neurotrophic factors: From molecule to man
209. Age-related changes in neuromuscular innervition
210. Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death
211. The specific force of single intact extensor digitorum longus and soleus mouse muscle fibers declines with aging
212. The numbers of limb motor neurons in the human lumbosacral cord throughout life
213. The estimated numbers and relative sizes of thenar motor units as selected by multiple point stimulation in young and older adults
214. Age changes of motor innervation and acetylcholine receptor distribution on human skeletal muscle fibres
215. Aging of the neuromuscular apparatus
216. Age, gender, and muscular strength
217. Age-related changes in diaphragm muscle contractile properties and myosin heavy chain isoforms
218. Age-related remodeling of neuromuscular junctions on type-identified diaphragm fibers
219. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients
220. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients
221. Neuromuscular and haemodynamic effects of mivacurium in elderly and young adult patients
222. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults
223. Age-dependent dose-response relationship of ORG NC 45 in anaesthetized patients
224. Distribution, elimination, and action of vecuronium in the elderly
225. Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients
226. Duration of action of neostigmine and pyridostigmine in the elderly
227. Aging alters the pharmacokinetics of pyridostigmine
228. Dose-response relationships for neostigmine antagonism of vecuronium-induced neuromuscular block in adults and the elderly
229. Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients
230. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia
231. Up-and-down regulation of skeletal muscle acetylcholine receptors: Effects on neuromuscular blockers
232. Developmental regulation of nicotinic acetylcholine receptors
233. Effect of partial denervation on motor units in the ageing rat medial gastrocnemius
234. Primary structure and expression of a sodium channel characteristic of denervated and immature rat skeletal muscle
235. Basic and clinical pharmacology of the acetylcholine receptor: Implications for the use of neuromuscular relaxants
236. Prolonged d-tubocurarine infusion and/or immobilization cause upregulation of acetylcholine receptors and hyperkalemia to succinylcholine in rats
237. Acetylcholine receptors and myasthenia
238. Neuromuscular complications in the ICU: The spectrum of critical illness-related conditions causing muscular weakness and weaning failure
239. A study of sensitivity to curare in myasthenic disorders using a regional technique
240. The relation between tetanic fade and receptor occlusion in the presence of competitive neuromuscular block
241. Changes in truncated trkB and p75 receptor expression in the rat spinal cord following spinal cord hemisection and spinal cord hemisection plus neurotrophin treatment
242. Cardiovascular collapse following succinylcholine in a paraplegic patient
243. Succinylcholine-induced hyperkalemia in patients with ruptured cerebral aneurysms
244. Cardiac arrest following succinylcholine in patients with central nervous system injuries
245. Pathophysiology of hyperkalemia induced by succinylcholine
246. Succinylcholine hyperkalemia after burns
247. Succinylcholine-induced hyperkalemia in patients with complete spinal cord injuries
248. Immobilization depresses insulin signaling in skeletal muscle
249. Mechanisms for the paradoxical resistance to d-tubocurarine during immobilization-induced muscle atrophy
250. Disuse atrophy with resistance to pancuronium
251. Suxamethonium-induced cardiac arrest and death following 5 days of immobilization
252. Tubocurarine sensitivity of the diaphragm after limb immobilization
253. The onset of disuse-related potassium efflux to succinylcholine
254. Causes of neuromuscular weakness in the intensive care unit: A study of ninety-two patients
255. Critical illness polyneuropathy and myopathy (CIPNM): Evidence for local immune activation by cytokine-expression in the muscle tissue
256. Cecal ligation and puncture peritonitis model shows decreased nicotinic acetylcholine receptor numbers in rat muscle: Immunopathologic mechanisms?
257. Critical illness polyneuropathy
258. Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium
259. Changes in acetylcholine receptor number in muscle from critically ill patients receiving muscle relaxants: An investigation of the molecular mechanism of prolonged paralysis
260. Persistent paralysis in critically ill patients after long-term administration of vecuronium
261. Toxicity of antibacterial agents: Mechanism of action on mammalian cells
262. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients
263. The complex genetic aetiology of multiple sclerosis
264. Multiple sclerosis associated with defects in neuromuscular transmission
265. Anesthesia for the obstetric patient with multiple sclerosis
266. Multiple sclerosis and surgery
267. Lumbar epidural anesthesia in a patient with multiple sclerosis
268. Fast and slow mammalian muscles after denervation
269. Action potentials in fast- and slow-twitch mammalian muscles during reinnervation and development
270. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death
271. Oxidative stress in amyotrophic lateral sclerosis
272. IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebellar Purkinje cells and in isolated channel protein in lipid bilayer
273. Immunoglobulins from amyotrophic lateral sclerosis patients enhance spontaneous transmitter release from motor-nerve terminals
274. Amyotrophic lateral sclerosis: Serum factors enhance spontaneous and evoked transmitter release at the neuromuscular junction
275. Long-term neuromuscular dysfunction produced by passive transfer of amyotrophic lateral sclerosis immunoglobulins
276. Circulatory collapse following succinylcholine: Report of a patient with diffuse lower motor neuron disease
277. Epidural anesthesia for patients with amyotrophic lateral sclerosis
278. Pathogenesis of Guillain-Barre syndrome
279. Localization of GM1 and Gal(beta 1-3)GaNAc antigenic determinants in peripheral nerve
280. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: A macro-patch-clamp study
281. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome
282. Electrophysiologic studies in the Guillain-Barre syndrome: Effects of plasma exchange and antibody rebound
283. Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barre syndrome
284. Cardiac arrest in Guillain-Barre syndrome and the use of suxamethonium
285. Pregnancy, anaesthesia and Guillain Barre syndrome
286. Cardiac arrest after succinylcholine administration in a pregnant patient recovered from Guillain-Barre syndrome
287. Hypo- and hypersensitivity to vecuronium in a patient with Guillain-Barre syndrome
288. Guillain-Barre syndrome after epidural anesthesia: Direct nerve root damage may trigger disease
289. Genetic and clinical aspects of Charcot-Marie-Tooth's disease
290. Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients
291. Clinical and pathological observations in men lacking the gap junction protein connexin 32
292. Connexin mutations in X-linked Charcot-Marie-Tooth disease
293. New functions for gap junctions
294. Gap junction wiring: A 'new' principle in cell-to-cell communication in the nervous system?
295. Hereditary peripheral neuropathies: Clinical forms, genetics, and molecular mechanisms
296. Uniform slowing of conduction velocities in Charcot-Marie-Tooth polyneuropathy type 1
297. Motor and sensory disability has a strong relationship to induction dose of thiopental in patients with the hypertropic variety of Charcot-Marie-Tooth syndrome
298. Anesthetic management for cesarean section of a patient with Charcot-Marie-Tooth disease
299. Respiratory muscle weakness in Charcot-Marie-Tooth disease: A field study
300. Response to atracurium and mivacurium in a patient with Charcot-Marie-Tooth disease
301. Anaesthesia for Charcot-Marie-Tooth disease: A review of 86 cases
302. Malignant hyperthermia during sevoflurane administration
303. Muscular dystrophy
304. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy
305. The coexistence of embryonic and adult acetylcholine receptors in sarcolermna of mdx dystrophic mouse muscle: An effect of regeneration or muscular dystrophy?
306. The neurobiology of duchenne muscular dystrophy: Learning lessons from muscle?
307. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy
308. Suxamethonium-induced cardiac arrest in unsuspected pseudohypertrophic muscular dystrophy: Case report
309. Succinylcholine-induced cardiac arrest in unsuspected Duchenne muscular dystrophy
310. The response of patients with Duchenne's muscular dystrophy to neuromuscular blockade with vecuronium
311. Malignant hyperthermia in a patient with Becker muscular dystrophy: Dystrophin analysis and caffeine contracture study
312. Human sodium channel myotonia: Slowed channel inactivation due to substitutions for a glycine within the III-IV linker
313. Multimeric structure of CIC-1 chloride channel revealed by mutations in dominant myotonia congenita (Thomsen)
314. Cloning of the essential myotonic dystrophy region and mapping of the putative defect
315. Novel isoform of myotonin protein kinase: Gene product of myotonic dystrophy is localized in the sarcoplasmic reticulum of skeletal muscle
316. Skeletal muscle sarcoplasmic reticulum phenotype in myotonic dystrophy
317. Sodium channel defects in myotonia and periodic paralysis
318. Contractile properties of single muscle fibers in myotonic dystrophy
319. Vecuronium for muscle relaxation in patients with dystrophia myotonica
320. Dystrophia myotonica and succinylcholine
321. Hazards of neostigmine in patients with neuromuscular disorders: Report of two cases
322. Dystrophica myotonia and suxamethonium
323. Malignant hyperthermia in myotonia congenita
324. Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia?
325. Congenital myotonic dystrophy in children: A review of ten years' experience
326. The effect of pregnancy on dystrophia myotonica
327. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits
328. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes
329. Morphology of the myasthenic neuromuscular junction
330. Myasthenia gravis and its animal model: T cell receptor expression in an antibody mediated autoimmune disease
331. Antigen mimicry in autoimmune disease: Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of Myasthenia gravis?
332. Newly recognized congenital myasthenic syndromes: I. Congenital paucity of synaptic vesicles and reduced quantal release. II. High-conductance fast-channel syndrome. III. Abnormal acetylcholine receptor (AChR) interaction with acetylcholine. IV. AChR deficiency and short channel-open time
333. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy
334. Serum and plasma from patients with Lambert-Eaton myasthenic syndrome reduce depolarization-dependent uptake of 45Ca2+ into rat cortical synaptosomes
335. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome
336. Anaesthesia and myasthenia gravis
337. Resistance to succinylcholine in myasthenia gravis: A dose-response study
338. Mivacurium chloride and myasthenia gravis
339. Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis
340. End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit
341. Multivariate determinants of the need for postoperative ventilation in myasthenia gravis
342. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma
343. Mitochondrial DNA expression in mitochondrial myopathics and coordinated expression of nuclear genes involved in ATP production
344. Ragged red fibers in normal aging and inflammatory myopathy
345. Mitochondrial disorders: Clinical and genetic features
346. Mitochondrial disease in superoxide dismutase 2 mutant mice
347. Mitochondrial myopathy caused by long-term zidovudine therapy
348. Mitochondrial involvement in post-tetanic potentiation of synaptic transmission
349. Electrophysiological study of neuromuscular system involvement in mitochondrial cytopathy
350. Kearns-Sayer syndrome and pancuronium-succinylcholine-induced neuromuscular blockade
351. Sensitivity to mivacurium in a patient with mitochondrial myopathy
352. Myopathy and succinylcholine sensitivity
353. Chronic rhabdomyolysis disclosing mitochondriopathy and malignant hyperthermia susceptibility
354. Ion channels in epilepsy
355. Hyperkalemic periodic paralysis and the adult muscle sodium channel alpha-subunit gene
356. Hyperkalaemic periodic paralysis and anaesthesia
357. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree
358. Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31-32 in three European families
359. Adynamia episodica hereditaria with myotonia: A non-inactivating sodium current and the effect of extracellular pH
360. Anesthetic management of hypokalemic periodic paralysis
361. Anesthetic experiences in a family with hypokalemic familial periodic paralysis
362. Malignant hyperthermia in a patient with hypokalemic periodic paralysis
363. Anesthetic management of familial hypokalemic periodic paralysis during parturition
364. Serum potassium levels after induction of epidural anaesthesia using mepivacaine with and without adrenaline
365. The genetic basis of malignant hyperthermia
366. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families
367. Malignant hyperthermia: Advances in clinical management and diagnosis
368. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor
369. Segregation of malignant hyperthermia, central core disease and chromosome 19 markers
370. Central core disease: Ultrastructure of the sarcoplasmic reticulum and T-tubules
371. Central core disease: Clinical features in 13 patients
372. Human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes predict efficacy of halogenated compounds that disobey the Meyer-Overton rule
373. Role of dystrophin isoforms and associated proteins in muscular dystrophy
374. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin
375. The childhood muscular dystrophies: Making order out of chaos
376. Mutations in the laminin alpha2-chain gene in two children with early-onset muscular dystrophy
377. Fukutin protein is expressed in neurons of the normal developing human brain but is reduced in Fukuyamatype congenital muscular dystrophy brain
378. Definitive molecular diagnosis of facioscapulohumeral dystrophy
379. Genetic analysis of postsynaptic differentiation at the vertebrate neuromuscular junction